Feature

Update on therapies for lymphoproliferative disorders


 

Diabetes mellitus as a late effect of the treatment of Hodgkin lymphoma.1
Two recent follow-up studies of childhood cancer patients who had been treated with abdominal radiation revealed an increased risk of diabetes mellitus (DM) in the survivors. In the past, many patients with a diagnosis of Hodgkin lymphoma (HL) were also treated with infradiaphragmatic radiation. The para-aortic and splenic fields used for this treatment encompasses most of the pancreas, including the tail. Since diabetes is a risk factor for cardiovascular disease, it is conceivable that an increase in diabetes in survivors of HL might contribute to their increased risk of cardiovascular disease. In this recent study of adults, the results of the treatment of 2,352 Dutch 5-year survivors of HL treatment who were younger than 51 years at the time of diagnosis were analyzed. Detailed records of their treatment and late effects of treatment were obtained, including information about DM, hypertension, hypercholesterolemia, smoking, and obesity. Radiation dose to the pancreas was estimated.

Click on the PDF icon at the top of this introduction to read the full article.

Recommended Reading

NHS cuts 5 blood cancer drugs from CDF, adds 1
MDedge Hematology and Oncology
Protein may hold key to treating resistant lymphomas
MDedge Hematology and Oncology
Survey reveals cancer survivors’ unmet needs
MDedge Hematology and Oncology
Biopsies don’t promote cancer spread, group finds
MDedge Hematology and Oncology
Product gets fast track designation for CTCL
MDedge Hematology and Oncology
CAR T-cell therapy gets orphan designation for DLBCL
MDedge Hematology and Oncology
Cord blood product gets orphan designation
MDedge Hematology and Oncology
Maintenance prolongs PFS, not OS, in relapsed CLL
MDedge Hematology and Oncology
HIV doesn’t hinder lymphoma patients’ response to ASCT
MDedge Hematology and Oncology
Older patients benefit from brentuximab treatment
MDedge Hematology and Oncology